BlackRock’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,799,818
| Closed | -$300M | – | 5527 |
|
|
2023
Q1 | $300M | Sell |
2,799,818
-7,886
| -0.3% | -$846K | 0.01% | 1258 |
|
|
2022
Q4 | $309M | Buy |
2,807,704
+673,432
| +32% | +$74.1M | 0.01% | 1216 |
|
|
2022
Q3 | $126M | Buy |
2,134,272
+319,310
| +18% | +$18.8M | ﹤0.01% | 1800 |
|
|
2022
Q2 | $51.2M | Sell |
1,814,962
-343,989
| -16% | -$9.71M | ﹤0.01% | 2449 |
|
|
2022
Q1 | $81.5M | Sell |
2,158,951
-1,818
| -0.1% | -$68.6K | ﹤0.01% | 2240 |
|
|
2021
Q4 | $85.4M | Buy |
2,160,769
+1,220,649
| +130% | +$48.3M | ﹤0.01% | 2291 |
|
|
2021
Q3 | $22.3M | Buy |
940,120
+942
| +0.1% | +$22.3K | ﹤0.01% | 3160 |
|
|
2021
Q2 | $23.1M | Buy |
939,178
+593,261
| +172% | +$14.6M | ﹤0.01% | 3162 |
|
|
2021
Q1 | $6.32M | Buy |
+345,917
| New | +$6.32M | ﹤0.01% | 3771 |
|